2 weeks Ago By ABMN Staff
Invesco Ltd. lifted its stake in Astrana Health, Inc. ( NASDAQ:ASTH – Free Report ) by 6.
9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 258,520 shares of the company’s stock after buying an additional 16,717 shares during the period. Invesco Ltd.
owned about 0.46% of Astrana Health worth $8,151,000 at the end of the most recent reporting period. Other hedge funds and other institutional investors have also modified their holdings of the company.
Envestnet Asset Management Inc. raised its stake in Astrana Health by 19.9% during the fourth quarter.
Envestnet Asset Management Inc. now owns 7,124 shares of the company’s stock worth $225,000 after acquiring an additional 1,184 shares in the last quarter. Rhenman & Partners Asset Management AB acquired a new stake in shares of Astrana Health during the 4th quarter worth about $2,522,000.
Pilgrim Partners Asia Pte Ltd bought a new position in Astrana Health during the 4th quarter valued at about $40,000. Wells Fargo & Company MN lifted its holdings in Astrana Health by 41.5% during the 4th quarter.
Wells Fargo & Company MN now owns 22,484 shares of the company’s stock valued at $709,000 after purchasing an additional 6,596 shares during the last quarter. Finally, ExodusPoint Capital Management LP acquired a new position in Astrana Health in the fourth quarter valued at about $1,140,000. Institutional investors own 52.
77% of the company’s stock. Analyst Upgrades and Downgrades A number of research firms have recently issued reports on ASTH. Robert W.
Baird cut their target price on shares of Astrana Health from $86.00 to $50.00 and set an “outperform” rating for the company in a research note on Monday, March 3rd.
Barclays began coverage on Astrana Health in a research note on Tuesday, April 1st. They issued an “equal weight” rating and a $36.00 price objective on the stock.
Truist Financial lowered their target price on Astrana Health from $50.00 to $46.00 and set a “buy” rating for the company in a research note on Tuesday, March 18th.
Stifel Nicolaus reduced their price target on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday, February 20th.
Finally, Bank of America decreased their price objective on shares of Astrana Health from $55.00 to $49.00 and set a “buy” rating on the stock in a report on Tuesday, March 4th.
Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $53.29.
Astrana Health Stock Up 1.7 % Shares of NASDAQ ASTH opened at $30.90 on Thursday.
Astrana Health, Inc. has a 1 year low of $23.12 and a 1 year high of $63.
20. The firm’s 50-day moving average is $31.49 and its 200-day moving average is $38.
71. The company has a current ratio of 1.91, a quick ratio of 1.
91 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $1.
55 billion, a PE ratio of 23.77, a price-to-earnings-growth ratio of 1.37 and a beta of 1.
04. Astrana Health ( NASDAQ:ASTH – Get Free Report ) last released its earnings results on Thursday, February 27th. The company reported ($0.
15) EPS for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.37).
The business had revenue of $665.21 million for the quarter, compared to analyst estimates of $617.24 million.
Astrana Health had a return on equity of 9.37% and a net margin of 3.63%.
Equities analysts expect that Astrana Health, Inc. will post 1.15 EPS for the current year.
Astrana Health Profile ( Free Report ) Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
Further Reading Want to see what other hedge funds are holding ASTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrana Health, Inc. ( NASDAQ:ASTH – Free Report ).
Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter ..
